Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Bardia, Aditya; M. Tolaney, Sara; Punie, Kevin; Loirat, Delphine; Oliveira, Mafalda; Kalinsky, Kevin; Zelnak, Amelia; Aftimos, Philippe; Dalenc, Florence; Sardesai, Sagar; Hamilton, Erika; Sharma, Priyanka; Recalde, Sabela; Ciruelos Gil, Eva; Traina, T; O’Shaughnessy, Joyce; Cortés, Javier; Tsai, Mu‐Hung; T. Vahdat, Linda; Dièras, Véronique; A. Carey, Lisa; S. Rugo, Hope; M. Goldenberg, David; Hong, Q.; Olivo, Martin; M. Itri, Loretta; A. Hurvitz, Sara

doi:10.1016/j.annonc.2021.06.002

Public

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Published in Annals of Oncology • Jun 8, 2021

Authors:

Aditya Bardia

Sara M. Tolaney

Kevin Punie

Abstract

BACKGROUND: The pivotal phase III ASCENT trial demonstrated improved survival outcomes associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti-Trop-2) antibody-drug conjugate linked with the topoisomerase-inhibitor SN-38, over single-agent chemotherapy treatment ...

Subject

Medicine

Internal medicine

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!